Copyright
©2013 Baishideng Publishing Group Co.
World J Hepatol. Jul 27, 2013; 5(7): 345-352
Published online Jul 27, 2013. doi: 10.4254/wjh.v5.i7.345
Published online Jul 27, 2013. doi: 10.4254/wjh.v5.i7.345
Studies | Therapeutic strategies | Phases | Primary outcomes |
Combinational therapy | |||
NCT01271504 | E7050 plus sorafenib vs sorafenib | Phase II | Adverse event |
NCT01033240 | CS-1008 plus sorafenib vs sorafenib | Phase II | TTP |
NCT01539018 | Tegafur-uracil plus sorafenib vs sorafenib | Phase II | TTP |
NCT01272557 | Doxorubicin plus sorafenib vs sorafenib | Phase II | TTP |
NCT01015833 | Doxorubicin plus sorafenib vs sorafenib | Phase III | OS |
NCT01214343 | Cisplatin/fluorouracil plus sorafenib vs sorafenib | Phase III | OS |
Second-line treatments | |||
NCT01507168 | GC33 vs placebo | Phase II | PFS |
NCT01273662 | Axitinib | Phase II | SD |
NCT00717756 | Lenalidomide | Phase II | RR |
NCT01545804 | Lenalidomide | Phase II | SD |
NCT01567930 | Temsirolimus | Phase II | Disease progression |
NCT01180959 | Erlotinib plus bevacizumab | Phase II | PFS |
NCT01140347 | Ramucirumabplus BSC vs placebo plus BSC | Phase III | PFS |
NCT01108705 | Brivanib plus BSC vs placebo plus BSC | Phase III | OS |
NCT00825955 | Brivanib plus BSC vs placebo plus BSC | Phase III | OS |
NCT01035229 | Everolimus plus BSC vs placebo plus BSC | Phase III | OS |
- Citation: Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013; 5(7): 345-352
- URL: https://www.wjgnet.com/1948-5182/full/v5/i7/345.htm
- DOI: https://dx.doi.org/10.4254/wjh.v5.i7.345